SRTA at a glance
Strata Critical Medical, Inc. (SRTA, SEC CIK 1779128) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Strata Critical Medical, Inc. (SRTA) reported revenue of $197.1 million (down 20.7% from FY2024) and net income of $41.3 million. Diluted EPS was $0.50.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Strata Critical Medical, Inc. (SRTA) shares worth $118.4 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by LAUCK ANDREW on November 5, 2026 of 2,000 shares at $5.00 per share.
- In the last 90 days, SRTA insiders reported 1 open-market purchase ($10K) and 0 open-market sales ($0) on Form 4, a net purchase of $10K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $197.1M
- −20.7% vs prior year
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$10K
- 13F holders
- 26 funds
- $118.4M · +2 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risks disclosed in the December 31, 2025 Form 10-K
- Carried-forward business risks could materially affect operations and financial condition
- Common-stock trading price risk from adverse business developments
- Forward-looking statement risk from actual results differing materially from expectations
Management Discussion & Analysis
- Revenue $74.1M, up 50.3% YoY from $49.3M, driven by Clinical revenue of $29.2M
- Total gross margin 22.7% vs 21.6% YoY, with Clinical margin 25.6% and Logistics margin 20.8%
- Best segment Clinical: $29.2M revenue and $7.5M gross profit, worst Logistics: $44.9M revenue, down 3.5% YoY
- Cash and equivalents $35.1M vs $31.0M, operating cash flow $19.0M vs $(40.6)M YoY
- $35.8M acquisition spending and $8.1M property investments, with $15.3M proceeds from Buyer Shares sales
- Outlook: $41.6M liquidity expected sufficient for current needs through 12 months, with donor supply flattening and clinician costs a headwind
AI summary of the SRTA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 results announced for quarter ended September 30, 2026
- Press release Exhibit 99.1 contains the financial results and investor-relevant performance details
Item EX-99.1: Item EX-99.1
- Q3 revenue $74.1M, up 50.3% year over year, driven by acquisitions and clinical revenue growth
- Clinical revenue $29.2M, up 20.3% sequentially, while Logistics revenue declined 3.5% to $44.9M
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 financial results for the quarter ended June 30, 2026 announced on August 4, 2026
- Detailed results and management commentary available in Exhibit 99.1, the accompanying press release
Item EX-99.1: Item EX-99.1
- Q2 revenue $72.5M, up 60.7% YoY, with Clinical revenue $24.3M and organic Clinical growth 15.1% sequentially
- Adjusted EBITDA $7.9M, margin 10.9%, up from $2.5M and 5.5% YoY, signaling improved operating leverage
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders elected William A. Heyburn and Andrew Lauck as Class II directors through the 2029 annual meeting
- Heyburn received 46,050,902 votes for, while Lauck received 39,525,159, indicating materially stronger support for Heyburn
AI summaries of SRTA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SRTA
Don't miss the next SRTA filing
- Alerts as it files. A push when SRTA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SRTA, by share count.
- Ask anything. An AI agent that reads every SRTA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| LAUCK ANDREW | Buy | Nov 5, 2026 | 2,000 | $5.00 |
| Wunsch Scott M | F | Oct 28, 2026 | 44,996 | $4.76 |
| Wunsch Scott M | A | Oct 28, 2026 | 57,173 | - |
| Wunsch Scott M | A | Oct 28, 2026 | 1,416 | - |
| Wunsch Scott M | A | Oct 28, 2026 | 57,173 | - |
| Heyburn William A. | F | Sep 24, 2026 | 98,356 | $5.27 |
| Tomkiel Melissa M. | F | Sep 24, 2026 | 90,797 | $5.27 |
| Heyburn William A. | A | Sep 24, 2026 | 177,858 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $248.7M | $197.1M |
| Gross Profit | - | $29.6M | $41.1M |
| Operating Income | - | -$33.9M | -$22.4M |
| Net Income | - | -$27.3M | $41.3M |
| Gross Margin | - | 11.9% | 20.9% |
| Op. Margin | - | -13.6% | -11.3% |
| Net Margin | - | -11.0% | 21.0% |
| Balance Sheet | |||
| Total Assets | - | $256.7M | $325.5M |
| Equity | - | $221.9M | $279.1M |
| ROE | - | -12.3% | 14.8% |
| Per Share | |||
| EPS | $-0.76 | $-0.35 | $0.50 |
| Cash Flow | |||
| Operating CF | - | -$2.5M | -$48.9M |
| CapEx | $2.1M | $30.9M | $9.6M |
Source: XBRL data in Strata Critical Medical, Inc. (SRTA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SRTA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $118.4M |
| Q2 2026 | 24 | $126.1M |
| Q1 2026 | 26 | $116.3M |
| Q4 2025 | 24 | $133.8M |
| Q3 2025 | 25 | $137.1M |
| Q2 2025 | 23 | $93.3M |
| Q1 2025 | 20 | $51.3M |
| Q4 2024 | 17 | $72.2M |
- State Street Corp+278.6K (+18%)
- AQR Capital Management+277.5K (+199%)
- Citigroup+244.2K (+46%)
- Goldman Sachs Group+216.1K (+46%)
- BNY Mellon+156.8K (+14%)
- Renaissance Technologies LLC−139.7K (-28%)
- JPMorgan Chase & Co−66.6K (-21%)
- Vanguard Portfolio Management LLC−61.4K (-12%)
- Wells Fargo & Co−43.4K (-75%)
- Northern Trust−29.5K (-4%)
- Raymond James Financial+300.0K
- Millennium Management+294.3K
- Citadel Advisors LLC+191.8K
- Two Sigma Investments+73.5K
- D.E. Shaw & Co+65.0K
- ARK Investment Management−2.73M
- Principal Financial Group−137.9K
- FMR LLC (Fidelity)−5.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 185 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SRTA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 9, 2026 | - | - | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 4 | Oct 30, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
Related Health Care companies
- DCGO · DocGo Inc.Services-Health Services
- WGS · GeneDx Holdings Corp.Services-Health Services
- INNV · InnovAge Holding Corp.Services-Health Services
- LFST · LifeStance Health Group, Inc.Services-Health Services
- OMDA · Omada Health, Inc.Services-Health Services
- PNTG · Pennant Group, Inc.Services-Health Services
- PRVA · Privia Health Group, Inc.Services-Health Services
- TALK · Talkspace, Inc.Services-Health Services
SRTA SEC filings: frequently asked questions
Are SRTA insiders buying or selling?
In the last 90 days, Strata Critical Medical, Inc. (SRTA) officers, directors and 10% owners reported 1 open-market purchase worth $9,998 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SRTA stock?
As of September 30, 2026, the largest Strata Critical Medical, Inc. (SRTA) holders among the 13F filers tracked by SignalX were Third Point LLC ($25.6 million), BlackRock ($24.9 million), Vanguard Capital Management LLC ($14.8 million), State Street Corp ($9.2 million), Dimensional Fund Advisors ($9.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SRTA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Strata Critical Medical, Inc. (SRTA) reported revenue of $197.1 million (down 20.7% from FY2024) and net income of $41.3 million. Diluted EPS was $0.50. The figures come from the XBRL data in the 10-K.
What did SRTA report in its latest 8-K?
Strata Critical Medical, Inc. (SRTA) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results announced for quarter ended September 30, 2026.
What are the latest SRTA SEC filings?
Strata Critical Medical, Inc. (SRTA) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 9, 2026.
What is SRTA's SEC CIK number?
Strata Critical Medical, Inc. (SRTA)'s SEC Central Index Key (CIK) is 1779128. EDGAR lists every SRTA filing under that number.
Ask anything about SRTA
The research agent reads SRTA's filings, financials, insider trades and 13F holders, then answers with sources.